The activation of MuRF‐1 and Atrogin‐1 can further promote the ubiquitination of substrates, enhance the degradation by proteasomes, and increase muscle atrophy, including in skeletal muscles, potentially leading to cancer cachexia.28, 29. The gene discussed is FBXO32; the disease is cancer.